ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
OSE Immunotherapeutics

OSE Immunotherapeutics (6OP)

8.90
0.19
(2.18%)
Closed 24 November 8:00AM
Realtime Data

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
8.90
Bid
8.86
Offer
8.94
Volume
0.00
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
8.71
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

6OP Latest News

Informations relatives au nombre total de droits de vote et d’actions composant le capital

Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 4 novembre 2024 – En application de l’article L. 233-8 II du Code de commerce et de l’article...

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis OSE...

OSE Immunotherapeutics Annonce des Résultats Cliniquement Probants et Statistiquement Significatifs de l’Étude de Phase 2 de l’Anticorps Anti-IL7R Lusvertikimab pour le Traitement de la Rectocolite Hémorragique

OSE Immunotherapeutics Annonce des Résultats Cliniquement Probants et Statistiquement Significatifs de l’Étude de Phase 2 de l’Anticorps Anti-IL7R Lusvertikimab pour le Traitement de la...

OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index

OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index NANTES, France, October 17, 6:00pm CET - OSE...

OSE Immunotherapeutics présente une nouvelle technologie bispécifique de « Cis-Démasquage » pour la conception de médicaments à base de cytokines avec un indice thérapeutique amélioré

OSE Immunotherapeutics présente une nouvelle technologie bispécifique de « Cis-Démasquage » pour la conception de médicaments à base de cytokines avec un indice thérapeutique amélioré OSE...

Informations relatives au nombre total de droits de vote et d’actions composant le capital

Informations relatives au nombre total de droits de vote et d’actions composant le capital al Nantes, le 2 octobre 2024 – En application de l’article L. 233-8 II du Code de commerce et de...

OSE Immunotherapeutics annonce des résultats semestriels 2024 remarquables et fait le point sur ses avancées

OSE Immunotherapeutics annonce des résultats semestriels 2024 remarquables et fait le point sur ses avancées OSE Immunotherapeutics annonce des résultats semestriels 2024 remarquables et fait le...

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update Financial and...

OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer

OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer OSE Immunotherapeutics Announces Global...

OSE Immunotherapeutics annonce le lancement international d’Artemia, l’étude de Phase 3 d’enregistrement du vaccin thérapeutique Tedopi® en deuxième ligne de traitement du cancer du poumon non à petites cellules

OSE Immunotherapeutics annonce le lancement international d’Artemia, l’étude de Phase 3 d’enregistrement du vaccin thérapeutique Tedopi® en deuxième ligne de traitement du cancer du poumon non à...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
988Eat & Beyond Global Holdings Inc
0.11 €
(83.33%)
90.79k
7M0ASpectra7 Microsystems Inc
0.14 €
(77.22%)
4.2k
TR9OTRS AG
17.10 €
(71.86%)
85.37k
RQ0DWave Quantum Inc
2.764 €
(46.63%)
2.02M
CFCaconnic AG
1.30 €
(46.07%)
129.74k
7S2Scotch Creek Ventures Inc
0.003 €
(-65.12%)
200
9HBKomo Plant Based Foods Inc
0.005 €
(-58.33%)
200
NL8Genesis Ai Corp
0.0058 €
(-52.46%)
19.55k
0PV2Moovly Media Inc
0.005 €
(-44.44%)
29.5k
BVU3St James Gold Corp
0.07 €
(-34.58%)
500
D7GNel ASA
0.2589 €
(3.15%)
6.92M
P1MPeninsula Energy Limited
0.0368 €
(2.22%)
3.23M
BT81PowerHouse Energy Group Plc
0.0126 €
(5.00%)
2.09M
RQ0DWave Quantum Inc
2.764 €
(46.63%)
2.02M
GHUADX Energy Ltd
0.032 €
(-1.84%)
1.58M

Discussion

View Full Feed
bb8675309 bb8675309 6 minutes ago
Interesting read: Companies that announced Major Layoffs and Hiring Freezes

real state of current economy. Market is being propped up by 7 companies. Buffet and Bezos holding record amount of cash.

https://www.afr.com/wealth/investing/buffett-s-499b-cash-hoard-is-an-ear
AVXL
dinogreeves dinogreeves 6 minutes ago
I know, SMCI so undervalued by at least 5 times from here for starters. The beautiful thing about it is the liquidity, the enormous inflow of dollar trading volume, it won't be long till this reaches 5-10% of NV*DA current market cap. SMCI is capturing a lot of attention now, thanks to "Hindenburg
SMCI
CaptBeer CaptBeer 7 minutes ago
In spite of the recent hoopla about LDL-C (The lower, the longer, the better), researchers are finding that significant residual risk for ASCVD remains. The pathways are complex, but in general Triglyceride Rich Lipoproteins, sometimes called Remanent Particles, are known to be better markers of ASC
AMRN
weedtrader420 weedtrader420 7 minutes ago
Awesome week for crypto🤑🥩🦞🍽️🍷
XRPUSD
zakattack zakattack 7 minutes ago
Make gncp current again
GNCP
WebSlinger WebSlinger 8 minutes ago
OTC Markets says that they have a market cap of about $21 million.

As of 30 Jun, they had $725 million in cash. They also have about $8+ BILLION worth in assets.

Seems a just a tad oversold to me.... LOL
SAVEQ
BurgerKing82 BurgerKing82 9 minutes ago
Any potential here left?
CRCW
123P654 123P654 9 minutes ago
Duly interested barry. ✔️
ECMH
FMDK FMDK 10 minutes ago
What I will definitely not do is buy new shares and run the risk of throwing even more money at this lousy management.
MVNT
HGilS HGilS 11 minutes ago
This should not be a priority.

#1 priority: launches
#2 priority R&d and pipeline
~~~~> higher revenues, higher profit, and buyout.

The real and only way for Nasrat to become ultra rich. And for us too.
ELTP
joe botts joe botts 11 minutes ago
Lol... another WATCH date? Promise it will still be REVOKED!
Papa Grizz Papa Grizz 11 minutes ago
Moonster, why belittle us all here. Just maybe we're not all poor peeps as u say, or maybe peeps here trying to get ahead in life with Shiba or maybe U need to go back a year or two on this thread and learn some past info about Team Shiba Army. Jus sayn-side note 771 following now
SHIBUSD
RuudSaltis RuudSaltis 13 minutes ago
I wish it was true that only facts, quality and the best product do count. Unfortunately it’s not the case, there are many examples in the tech world where the best never did win. The electric car is a great example (early 1900)! But VHS and Betacam also and there are many more. It’s not a nice and
LWLG
FMDK FMDK 13 minutes ago
I have no idea what you intend to do. Personally, I will hold the stock until it either bears enormous fruit or suffers a total loss.
MVNT
jdcpa1 jdcpa1 13 minutes ago
I guess you think you're some kind of a financial wizard, although you are one of the more clueless on the board. Look up net operating loss carryforwards within the federal tax code guidelines and tell us what you learn. Your entire post had now been debunked just like all your other baseless BS po
SPZI
Red_Right_Hand Red_Right_Hand 13 minutes ago
Askan et al, November 2024, Personalized Treatment in Neuro-oncology: Post-EANO 2024 Reflections

"The biology and diversity of glioblastoma in fact crave for personalized medical oncology approaches and in fact, promising results have already emerged both with targeted therapies and
NWBO
Seminole Red Seminole Red 14 minutes ago
I hope we have that choice.....
dexprs dexprs 14 minutes ago
For the last 95 years following two 20+% years on the market the average return had been an 8.9% gain. Some think we should have a down year in 2025, but the stats do not confirm that.
Seminole Red Seminole Red 15 minutes ago
thats funny
tw0122 tw0122 15 minutes ago
INTC NVDA
QuantumOasis152 QuantumOasis152 15 minutes ago
Glen, I am a big buyer at .62 cents.
nice to see someone else recognize risk free high potential real estate.
Would you give commentary to how you see your charts?
ZVIA
nelson1234 nelson1234 16 minutes ago
My son was just made VP at BBT & MSD Partners, he's 26. Who wudda thunk? Especially since he's not an Ivy League or equiv grad. Anyway, nice thanksgiving news..........
1vman 1vman 18 minutes ago
***** 🤪YESSIR !!!🟥 Lose lose !! 🟥🟥🟥 huge reverse split on the table for this stock to survive

ENOUGH SAID HUZZAH !!!
UBQU
trader53 trader53 18 minutes ago
DPLS - I'm Dreaming of a DPLS Christmas!


https://www.youtube.com/watch?v=GJ36gbGlm8Y
DPLS

Your Recent History

Delayed Upgrade Clock